Proactive Investors - Run By Investors For Investors

PreveCeutical granted C$300K loan; announces resignation of board member

In addition to the loan, the health sciences company announced board member Greg Reid has stepped down to focus on other opportunities
eye looking at microscope
PreveCeutical develops innovative options for preventive and curative therapies using organic products

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) announced Monday that it has secured a C$300,000 loan as part of an agreement with the health sciences company’s Executive Chairman and CEO Stephen Van Deventer.

As the lender, Van Deventer was also granted 5 million bonus warrants entitling him to purchase shares at an exercise price of C$0.06 for one year following the grant date.

Shares of the health sciences company shot up 10% on Monday morning to sit at C$0.06 in Toronto and traded at US$0.04 on OTC markets.

READ: PreveCeutical Medical wins approval to acquire human tissue for final phase of Sol-gel technology testing

The loan has a one-year term and will generate interest at a rate of 5% per year, compounded semi-annually, the company said in a statement. It will be used for general working capital purposes.

PreveCeutical informed investors that at the time of the loan neither the fair market value of the subject matter or the consideration for the loan exceeded 25% of the company's market capitalization, as per Ontario Securities Commission legislation.

The Vancouver-based company also announced that Greg Reid has stepped down as director of the company in order to focus on his filmmaking career.

"Greg has served on the PreveCeutical board of directors since the company went public in 2017,” said Dr. Mak Jawadekar, the company’s president and chief science officer, in a statement.

“He has made many contributions to the success and growth of the company, drawing on his wealth of experience and contacts from his successful business career. On behalf of the board of directors, the management team and our shareholders, I thank Greg and wish him all the best in the future."

--Updated share price--

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
An illustration of Ozop's BLIF technique
March 31 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
man pointing to brain
April 25 2019
Brain Scientific’s EEG technology is far cheaper and less bulky than a traditional EEG system, but provides EEG tracings of the same quality

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use